Terray Therapeutics develops small‑molecule therapeutics by combining generative AI, ultra‑high‑throughput experimentation, biology, medicinal chemistry, automation, and nanotechnology. Its integrated AI platform, tNova, and chemistry foundation model COATI power both internal programs and partnered discovery efforts. The company reports it has quantitatively measured more than 5 billion target–ligand interactions in the past three years—roughly 50× the entirety of publicly available chemistry data—and that this dataset is doubling annually. Terray applies these capabilities to an internal pipeline focused on immunological diseases and to multi‑target partnerships with Bristol Myers Squibb and Calico. Proceeds from the Series B will advance internal programs into the clinic and expand the tNova platform and associated AI tools. Since its Series A in 2021, Terray has raised over $200 million in equity financing to date. Terray Therapeutics, led by CEO Jacob Berlin, develops small-molecule therapeutics by integrating generative AI with high-throughput experimentation, biology, medicinal chemistry, automation, and nanotechnology. Its platform combines experimentation and computation to build ligand- and structure-based models aimed at accelerating discovery of challenging therapeutic targets. The company plans to develop comprehensive chemistry foundation models and will leverage NVIDIA DGX Cloud and the NVIDIA BioNeMo cloud service to scale and optimize those models. Terray intends to use its proprietary experimental datasets to train both ligand-based and structure-based generative models to propel its pipeline toward the clinic. Financially, Terray received an investment from NVentures alongside a syndicate of new and existing institutional investors; the amount of the financing was not disclosed. Named individual investors in the syndicate include John Maraganore and Bassil Dahiyat. Terray Therapeutics builds integrated computational and experimental platforms that generate scaled, agnostic chemical data to power computational learning and reveal new molecular interactions. The company combines AI, synthetic chemistry, automation and nanotechnology to propel drug discovery into the information age. Terray is led by CEO Jacob Berlin and is advancing a preclinical pipeline alongside discovery partnerships. The company intends to use the Series A proceeds to advance its preclinical programs and its discovery collaborations. This Series A follows a previously unannounced $20 million seed round co-led by Digitalis Ventures and Two Sigma Ventures. Terray is headquartered in Pasadena, California.

Total raised

$180M

Funding rounds

3

Latest round

Series B

Latest activity

Oct 2024